Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

• T-cell densities at baseline effectively distinguish responders from non-responders in urothelial cancer.
• In ipilimumab-high cohorts, responders showed significantly higher T-cell densities than non-responders.
• The analysis focused on T-cell subsets in cohorts receiving ipilimumab-high versus ipilimumab-low treatments.
• Findings support the potential for T-cell subset analysis in predicting treatment responses in urothelial cancer.